Speaker

Julian Dopstadt

Director, Eli Lilly

Julian Dopstadt, Director at Eli Lilly, spoke at 4th Covalent Drug Discovery & Development Summit (Boston, United States of America, 20–22 Oct 2026) in the session “Fireside Chat: Interpreting Preclinical Safety Data to Support First in Human & Early Clinical Decisions for Covalent Drugs”.

Conferences: 1
Keynotes: 0
Upcoming: 0

Pharmacy & Pharmaceutical Sciences

Past appearances

4th Covalent Drug Discovery & Development Summit
20–22 Oct 2026Boston, United States of America
- PanelFireside Chat: Interpreting Preclinical Safety Data to Support First in Human & Early Clinical Decisions for Covalent DrugsWith Rhamy Zeid
- SpeakerTranslating Covalent Drug Candidates from Concept to Clinic: DMPK & Clinical Pharmacology Strategies for Patient Benefit

More speakers at 4th Covalent Drug Discovery & Development Summit

David Anderson
Executive Director, Aclaris Therapeutics
Sara Buhrlage
Associate Professor, Biological Chemistry & Molecular Pharmacology, Dana-Farber Cancer Institute
Antony Burton
Associate Director, Chemical Biology & Proteomics, Dunad Therapeutics
Jianwei (John) Che
Core Director, Dana-Farber Cancer Institute
Jay Duffner
Director & Head of Discovery Biology, Frontier Medicines
Alex Federation
Co-Founder and Chief Executive Officer, Talus Bio

See all 20 speakers on the event page

This profile is built from conference programmes published on kongre.net. It has not been claimed or confirmed by Julian Dopstadt, and it lists only the talks, sessions and presentations named in those programmes.

Is this you? Claim this profile — every request is read by a person before anything is linked.

To ask for a correction or for this profile to be removed, email [email protected].